LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, announced today that its President and CEO, Steven A. Kriegsman, will be the featured guest on the NASDAQ CEO Signature Series webcast to be held on Tuesday, September 23. In his interview with veteran business journalist Sasha Salama, Mr. Kriegsman plans to discuss CytRx’s planned acquisition of Innovive Pharmaceuticals, Inc., through which CytRx expects to add to its drug development pipeline the drug candidate tamibarotene, which is currently in registration studies for the treatment of acute promyelocytic leukemia (APL). Mr. Kriegsman will also discuss CytRx’s leading molecular chaperone technology platform, including its planned clinical development of iroxanadine in patients with diabetic foot ulcers and other ongoing drug discovery efforts.
